Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Bids $2.4 Billion To Acquire Norwegian Biotech Partner Algeta

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer would gain full control of the potential blockbuster prostate cancer therapy, Xofigo, if successful.

You may also be interested in...



Bayer Targets Endometriosis, Fibroids In Oxford University Alliance

Women’s health is the focus of a two- to five-year research alliance between the German conglomerate and one of Europe’s largest biomedical research centers.

Bayer/Algeta’s Xofigo Brings New Mechanism To Prostate Cancer Field

FDA approved the first alpha particle-emitting radioactive therapeutic agent, Bayer/Algeta’s Xofigo (radium Ra 223 dichloride), for prostate cancer patients with symptomatic bone metastases, three months ahead of the expected PDUFA date.

Algeta Recruits Bayer To Deliver Prostate Cancer Drug Alpharadin To Market

Big Pharma still hot for castration-resistant prostate cancer drugs, despite Phase III burns in the past.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel